>

Pamela Craig - Merck Independent Director

<div class='circular--portrait' style='background:#FF6600;color: white;font-size:3em;padding-top: 40px;;'>MRK</div>
MRK -- USA Stock  

Fiscal Quarter End: March 31, 2020  

  Director
Ms. Pamela J. Craig serves as Independent Directorof the Company. She served as the chief financial officer of Accenture, a global management consulting, technology services and outsourcing company, from 2006 until her retirement in 2013. During her 34 years at Accenture, she held a variety of consulting, line management, operational and finance leadership roles. Ms. Craig is currently a senior advisor for Teneo, a global advisory firm
Age: 61  Director Since 2015  MBA    
908 735-1500  www.merck.com
Craig is a Phi Beta Kappa graduate of Smith College and earned an MBA from New York University. She serves as a member of the board of directors of Akamai Technologies, a leading worldwide provider of internet optimization services, where she also serves as audit committee chair and as a member of the compensation committee. She also serves as a board member and M&A committee member of VMware, Inc., a global technology leader in virtualization and cloud infrastructure. Additionally, Ms. Craig serves on the board of directors and audit committee of WalMart Stores, Inc.

Management Efficiency

The company has 27.59 B in debt with debt to equity (D/E) ratio of 99.4 . This implies that the company may be unable to create cash to meet all of its financial commitments. Merck has Current Ratio of 1.19 demonstrating that it may not be capable to disburse its financial commitments when the payables are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Jose BaselgaBristol Myers Squibb Company
2018
Ralph AlvarezEli Lilly And Company
2009
Ronald BlaylockPfizer
2017
Anne MulcahyJohnson Johnson
2012
Judy LewentGlaxoSmithKline PLC
2011
David HooverEli Lilly And Company
2009
William KaelinEli Lilly And Company
2012
Don CornwellPfizer
1997
Joseph EchevarriaPfizer
2015
Carolyn BertozziEli Lilly And Company
2017
Scott GottliebPfizer
2019
Lewis CampbellBristol Myers Squibb Company
2014
Shriti VaderaAstrazeneca PLC
2011
Marillyn HewsonJohnson Johnson
2018
Karen HornEli Lilly And Company
2012
Dinesh PaliwalBristol Myers Squibb Company
2013
Stacey CartwrightGlaxoSmithKline PLC
2011
Suzanne JohnsonPfizer
2007
Manvinder BangaGlaxoSmithKline PLC
2016
Ron TaylorAllergan Plc
2013
Ton BuechnerNovartis AG
2016

Company Summary

The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases neuromuscular blocking agents cholesterol modifying medicines and anti-bacterial and vaginal contraceptive products. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey. Merck operates under Drug Manufacturers - General classification in USA and is traded on BATS Exchange.Merck Company (MRK) is traded on BATS Exchange in USA. It is located in 2000 Galloping Hill Road, Kenilworth, NJ 07033, United States and employs 69,000 people. Merck Company was previously known as Merck Co and was traded on BATS Exchange under the symbol SGP. Merck is listed under Pharmaceutical Products category by Fama And French industry classification.

Merck Leadership Team

Thomas Glocer, Independent DirectorView
Craig Thompson, Independent DirectorView
Jennifer Zachary, Executive Vice President, General CounselView
Rochelle Lazarus, Independent DirectorView
Michael Rosenblatt, Executive Vice President Chief Medical OfficerView
Wendell Weeks, Independent DirectorView
Michael Holston, Executive Vice President Chief Ethics and Compliance OfficerView
Paul Rothman, Independent DirectorView
Mary Coe, Independent DirectorView
Adele Ambrose, Senior Vice President Chief Communications OfficerView
Joseph Romanelli, IR Contact OfficerView
Mirian GraddickWeir, Executive Vice President - Human ResourcesView
Peter Wendell, Independent DirectorView
John Noseworthy, Independent DirectorView
Leslie Brun, Lead Independent DirectorView
Julie Gerberding, Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy and Population HealthView
Inge Thulin, Independent DirectorView
Pamela Craig, Independent DirectorView
Patricia Russo, Independent DirectorView
Willie Deese, Executive Vice President and Presidentident - Merck Manufacturing DivisionView
Rita Karachun, Principal Accounting Officer, Sr. VP of Fin. and Global ControllerView
Robert Davis, Executive Vice President, Global Services, Chief Financial OfficerView
Robert Kidder, Independent DirectorView
Thomas Cech, Independent DirectorView
Michael Nally, Executive Vice President, Chief Marketing OfficerView
Clark Golestani, CIO and Executive VPView
William Harrison, Lead Independent DirectorView
Roger Perlmutter, Executive Vice President and Presidentident - Merck Research LaboratoriesView
Ashley Watson, Senior Vice President Chief Ethics and Compliance OfficerView
Steven Mizell, Executive Vice President, Chief Human Resources Officer, Human ResourcesView
Jim Scholefield, Executive Vice President, Chief Information and Digital OfficerView
Sanat Chattopadhyay, Executive Vice President and President - Merck Manufacturing DivisionView
Adam Schechter, President of Global Human Health and Executive VPView
Carlos Represas, Independent DirectorView
Richard DeLuca, Executive Vice President and Presidentident - Merck Animal HealthView
Kenneth Frazier, Chairman of the Board, President, Chief Executive OfficerView
Frank Clyburn, Executive Vice President, Chief Commercial OfficerView

Stock Performance Indicators

Current Sentiment - MRK

Merck Investor Sentiment

Predominant part of Macroaxis users are now bullish on Merck Company. What is your trading attitude regarding investing in Merck Company? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally see Stocks Correlation. Please also try Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.